Boehringer scores COPD win for Striverdi Respimat
This article was originally published in Scrip
Executive Summary
The FDA on 31 July approved another new therapy for chronic obstructive pulmonary disease (COPD) – this time Boehringer Ingelheim's long-acting beta-agonist (LABA) Striverdi Respimat (olodaterol) inhalation spray.